Journal
THROMBOSIS AND HAEMOSTASIS
Volume 117, Issue 7, Pages 1249-1257Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH16-12-0911
Keywords
Antiplatelet agents; GP Ib alpha; GP VI; GP IIb/IIIa; PAR-1
Categories
Funding
- Scientific Research in Japan [24390202, 050452092]
- RIKEN
- Sanofi
- Pfizer
- Principal Research Fellowship of the National Health and Medical Research Council of Australia
- Bayerische Forschungsstiftung [AZ 1145-14]
- Deutsche Forschungsgemeinschaft [SFB1123/608]
- August-Lenz foundation
- Grants-in-Aid for Scientific Research [24390202] Funding Source: KAKEN
Ask authors/readers for more resources
Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib alpha, and directed against GPVI, GPIIb/IIIa (integrin alpha(IIb)beta(3)), the thrombin receptor PAR-1, and the ADP receptor P2Y(12). The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available